BioSpace News Archive

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces its participation in the 27th Annual American Society of Cell and Gene Therapy Meeting, taking place on May 7-11, 2024, in Baltimore, United States of America.

Bio-Techne Corporation and Novomol-Dx, a molecular diagnostics company, are pleased to announce the development of Bio-Marker Pathfinder, a first of its kind ocular biomarker kit, as a point-of-care application.

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system designed to carry nucleotides to be developed as cancer treatments and vaccines, has entered into a research collaboration agreement with SRI, an independent nonprofit research institute based in Silicon Valley, California

BeiGene, Ltd., a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company’s strategy, the progress it has made towards existing goals, and how it intends to achieve its bold new targets.

Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndrome.

United Imaging Healthcare, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, has released their 2023 annual report.

RELIEF THERAPEUTICS Holding SA announces the results of the extraordinary general meeting of shareholders, which took place in Geneva , Friday, April 26, 2024.

The annual general meeting in Orexo AB on 26 April 2024 resolved, in accordance with the nomination committee’s proposal, that the number of board members shall be five with no deputy board members.

The U.S. clinical trials market size was valued at USD 25.81 billion in 2023 and is poised to grow from USD 27.07 billion in 2024 to USD 41.57 billion by 2033, growing at a CAGR of 4.88% in the forecast period 2024-2033, the oncology segment accounted for the maximum revenue share of 27% in 2023.

Roivios, a pioneering clinical-stage medical device company dedicated to transforming kidney health, is thrilled to announce it has been awarded the prestigious Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its cutting-edge JuxtaFlow® Renal Assist Device (RAD).